News and Announcements
Mustang Resources Ruby Inventory Hits 147,000cts
- Published August 18, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Mustang Resources (ASX: MUS) has recently released information in relation its ruby inventory at the Montepuez project in Mozambique continues to grow, reaching 147,052 carats.
KEY TAKEAWAYS:
- Ruby inventory hits 147,000cts, and is on track to reach 200,00cts target planned for October 2017.
- Plant working at full capacity.
- Mustangs inaugural rough ruby auction has been scheduled for 27-30 October 2017.
- Leading global ruby buyers have confirmed their attendance at the auction.
- Recently opened/discovered bulk sampling kits.
- Started the process of converting exploration licences to mining concessions with tenure of 25 years.
Mustang Managing Director Christiaan Jordaan said that all project work streams were going well and are on track for the auction.
“We are highly encouraged by the positive responses and support received from customers to date,” Mr Jordaan said. “Mustang’s management team is confident of delivering a strong inaugural auction and continuing to advance towards our goal of establishing the Company as a globally significant ruby supplier.
We are very pleased with the current performance of our processing plant after solving the remaining water challenges and now achieving good daily recoveries of high quality rubies.”
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
